- Home
- NEXM vs CGTX Comparison
NEXM vs CGTX Comparison
Compare NEXM & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEXM | CGTX |
|---|---|---|
| Founded | N/A | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.2M | 132.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NEXM | CGTX |
|---|---|---|
| Price | $3.95 | $1.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 77.4K | ★ 974.0K |
| Earning Date | 02-20-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.37 | $0.22 |
| 52 Week High | $10.35 | $3.83 |
Technical Indicators
Market Signals| Indicator | NEXM | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.68 | 45.13 |
| Support Level | $3.85 | $1.34 |
| Resistance Level | $4.29 | $1.57 |
| Average True Range (ATR) | 0.25 | 0.11 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 47.44 | 31.03 |
Price Performance
Historical ComparisonAbout NEXM NexMetals Mining Corp.
NexMetals Mining Corp is a mineral exploration and development company focused on discovering and advancing high-quality copper-nickel-cobalt-platinum element metals (Cu- Cu-Ni-Co-PGE) resources. The group prioritizes projects in stable, mining-friendly jurisdictions with supportive foreign investment and rule-of-law standards. Its projects are Botswana and Canada.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.